YIH
AVIR icon

Y-Intercept (HK)’s Atea Pharmaceuticals AVIR Stock Holding History

Y-Intercept (HK)’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-28,882
Closed -$108K – 1059
2023
Q2 		$108K Buy
+28,882
New +$108K 0.01% 1079
2021
Q4 		– Sell
-8,270
Closed -$290K – 575
2021
Q3 		$290K Buy
+8,270
New +$229K 0.05% 472

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Y-Intercept (HK)'s AVIR Position: Q3 2023 in Review

Y-Intercept (HK) sold out of Atea Pharmaceuticals (AVIR) in Q3 2023, closing a stake of 28,882 shares — an estimated $108K sold.

Y-Intercept (HK) first reported a position in AVIR in Q3 2021 and held it in 2 quarters. The position peaked at $290K in Q3 2021. 119 funds tracked by Wall St. Rank hold AVIR as of Q3 2023.

  • Y-Intercept (HK) reported no remaining Atea Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Y-Intercept (HK) sold 28,882 Atea Pharmaceuticals shares in Q3 2023, an estimated $108K.
  • Y-Intercept (HK) first reported a position in Atea Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • Y-Intercept (HK)'s Atea Pharmaceuticals position peaked at $290K in Q3 2021.
  • 119 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q3 2023.

Based on Y-Intercept (HK)'s 13F filing for Q3 2023, filed 14 Nov 2023.